RSS-Feed abonnieren
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.4103/0970-0358.173101
Fibrous dysplasia and cherubism
Publikationsverlauf
Publikationsdatum:
26. August 2019 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00042863/201503/lookinside/thumbnails/10-4103-0970-0358-173101_00236-1.jpg)
ABSTRACT
Fibrous dysplasia (FD) is a non-malignant fibro-osseous bony lesion in which the involved bone/bones gradually get converted into expanding cystic and fibrous tissue. The underlying defect in FD is post-natal mutation of GNAS1 gene, which leads to the proliferation and activation of undifferentiated mesenchymal cells arresting the bone development in woven phase and ultimately converting them into fibro-osseous cystic tissue. Cherubism is a hereditary form of fibrous dysplasia in which the causative factor is transmission of autosomal dominant SH3BP2 gene mutation. The disease may present in two distinct forms, a less severe and limited monostotic form, and a more aggressive and more widespread polyostotic form. Polyostotic form may be associated with various endocrine abnormalities, which require active management apart from the management of FD. Management of FD is not free from controversies. While total surgical excision of the involved area and reconstruction using newer micro-vascular technique is the only definitive treatment available from the curative point of view, but this can be only offered to monostotic and very few polyostotic lesions. In polyostotic varieties on many occasions these radical surgeries are very deforming in these slow growing lesions and so their indication is highly debated. The treatment of cranio-facial fibrous dysplasia should be highly individualized, depending on the fact that the clinical behavior of lesion is variable at various ages and in individual patients. A more conservative approach in the form of aesthetic recontouring of deformed bone, orthodontic occlusal correction, and watchful expectancy may be the more accepted form of treatment in young patients. Newer generation real-time imaging guidance during recontouring surgery adds to accuracy and safety of these procedures. Regular clinical and radiological follow up is required to watch for quiescence, regression or reactivation of the disease process. Patients must be warned and watched for any sign of nerve compression, especially visual impairment due to optic nerve compression. Rather than going for prophylactic optic canal decompression (which does more harm than good), optic nerve decompression should be done in symptomatic patients only, and preferably be done via minimal invasive endoscopic neuro-surgical approach than the conventional more morbid open craniotomy approach. There is growing research and possibilities that newer generation bisphosphonate medication may change the management scenario, as these medications show encouraging response in not only reducing the osteoclastic activity, but simultaneously also stimulating the osteoblastic and osteocytic activities. The explosion of genetic research and stem cell therapy may lead to better understanding and subsequently better treatment of FD in future.
-
REFERENCES
- 1 Adetayo OA, Salcedo SE, Borad V, Richards SS, Workman AD, Ray AO. Fibrous dysplasia: An overview of disease process, indications for surgical management, and a case report. Eplasty 2015; 15: e6
- 2 Lichtenstein L. Diseases of Bone and Joints. 2nd ed. St. Louis: CV Mosby; 1975: p. 244
- 3 Greer Jr RO, Rohrer MD, Young SK. Nonodontogenic tumors, clinical evaluation and pathology. In: Thawley SE, Panje WR. editors Comprehensive Management of Head and Neck Tumors. Philadelphia: WB Saunders; 1987: p. 1510
- 4 Leong LT, Ming BJ. Craniofacial fibrous dysplasia involving the orbit: A case report and literature review. Asia Pac J Ophthalmol (Phila) 2015; 4: 151-4
- 5 Mansilla-Lory J, Amezcua-Guerra LM, Vargas-Rodriguez A, Fernadez-Tapia S, Leboreiro I, Resnick D. et al Leontiasis ossea: A paleopathologic case report. J Clin Rheumatol 2007; 13: 269-72
- 6 Kuznetsov SA, Cherman N, Riminucci M, Collins MT, Robey PG, Bianco P. Age-dependent demise of GNAS-mutated skeletal stem cells and “normalization” of fibrous dysplasia of bone. J Bone Miner Res 2008; 23: 1731-40
- 7 Matthew RD, William FE. Fibrous dysplasia: Pathophysiology, evaluation, and treatment. J Bone Joint Surg Am 2005; 87: 1848-64
- 8 Osada H, Sakamoto R, Seki K, Sekiya S. Accelerated bone turnover in pregnant women with McCune-Albright syndrome. Gynecol Obstet Invest 2005; 60: 102-7
- 9 Bowers CA, Altay T, Shah L, Couldwell WT. Pregnancy induced cystic degeneration of fibrous dysplasia. Can J Neurol Sci 2012; 39: 828-9
- 10 Kaplan FS, Fallon MD, Boden SD, Schimidt R, Senior M, Hadda JG. Estrogen receptors in bone in a patient with polyostotic fibrous dysplasia (McCune-Albright Syndrome). N Engl J Med 1988; 319: 421-5
- 11 Munksgaard PS, Salkus G, Iyer VV, Fisker RV. Mazabraud’s syndrome: Case report with literature review. Acta Radiol Short Rep 2013; 2: 204
- 12 Wirth WA, Leavitt D, Enzinger FM. Multiple intramuscular myxomas. Another extraskeletal manifestation of fibrous dysplasia. Cancer 1971; 27: 1167-73
- 13 Lichtenstein L, Jaffe HL. Fibrous dysplasia of bone. A condition affecting one, several or many bones, the graver cases of which may present abnormal pigmentation of skin, premature sexual development, hyperthyroidism or still other extraskeletal abnormalities. Arch Pathol 1942; 33: 777-816
- 14 Sujatha S, Jatti D. Neurofibromatosis and fibrous dysplasia manifesting in the same patient: A rare case report. J Investig Clin Dent 2015; 6: 77-80
- 15 Eversole LR, Sabes WR, Rovin S. Fibrous dysplasia: A nosologic problem in the diagnosis of fibro-osseous lesions of the jaws. J Oral Pathol 1972; 1: 189-220
- 16 Kushare IV, Colo D, Bakhshi H, Dormans JP. Fibrous dysplasia of the proximal femur: Surgical management options and outcomes. J Child Orthop 2014; 8: 505-11
- 17 Tan YC, Yu CC, Chang CN, Ma L, Chen YR. Optic nerve compression in craniofacial fibrous dysplasia: The role and indications for decompression. Plast Reconstr Surg 2007; 120: 1957-62
- 18 Laino L, Favia G, Menditti D, De Francesco F, Salerno C, Scivetti M. et al Confocal laser scanning microscopy analysis of 10 cases of craniofacial fibrous dysplasia. Ultrastruct Pathol 2015; 39: 231-4
- 19 Jaffe HL, Lichtenstein L. Fibrous dysplasia of bone. A condition affecting one, several or many bones, the graver cases of which may present with abnormal pigmentation of skin, premature sexual development, hyperthyroidism or still other extraskeletal abnormalities. Arch Pathol 1942; 33: 777-816
- 20 Collins MT, Singer FR, Eugster E. McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia. Orphanet J Rare Dis 2012; 7 Suppl (01) S4
- 21 Fitzpatrick KA, Taljanovic MS, Speer DP, Graham AR, Jacobson JA, Barnes GR. et al Imaging findings of fibrous dysplasia with histopathologic and intraoperative correlation. AJR Am J Roentgenol 2004; 182: 1389-98
- 22 Zhibin Y, Quanyong L, Libo C, Jun Z, Hankui L, Jifang Z. et al The role of radionuclide bone scintigraphy in fibrous dysplasia of bone. Clin Nucl Med 2004; 29: 177-80
- 23 Petrocelli M, Kretschmer W. Conservative treatment and implant rehabilitation of the mandible in a case of craniofacial fibrous dysplasia: A case report. J Oral Maxillofac Surg 2014; 72: 902 e1-6
- 24 Mäkitie AA, Törnwall J, Mäkitie O. Bisphosphonate treatment in craniofacial fibrous dysplasia - A case report and review of the literature. Clin Rheumatol 2008; 27: 809-12
- 25 Egner-Höbarth S, Welkerling H, Windhager R. Bisphosphonates in the therapy of fibrous dysplasia. Relevant data and practical aspects. Orthopade 2007; 36:124: 126-30
- 26 Boyce AM, Kelly MH, Brillante BA, Kushner H, Wientroub S, Riminucci M. et al A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone. J Clin Endocrinol Metab 2014; 99: 4133-40
- 27 Boyce AM, Chong WH, Yao J, Gafni RI, Kelly MH, Chamberlain CE. et al Denosumab treatment for fibrous dysplasia. J Bone Miner Res 2012; 27: 1462-70
- 28 Wu D, Ma J, Bao S, Guan H. Continuous effect with long-term safety in zoledronic acid therapy for polyostotic fibrous dysplasia with severe bone destruction. Rheumatol Int 2015; 35: 767-72
- 29 Ganda K, Seibel MJ. Rapid biochemical response to denosumab in fibrous dysplasia of bone: Report of two cases. Osteoporos Int 2014; 25: 777-82
- 30 Bowers CA, Taussky P, Couldwell WT. Surgical treatment of craniofacial fibrous dysplasia in adults. Neurosurg Rev 2014; 37: 47-53
- 31 Lauritzen C, Alberius P, Santanelli F, Vällfors B, Lilja J, Stephensen H. Repositioning of craniofacial tumorous bone after autoclaving. Scand J Plast Reconstr Surg Hand Surg 1991; 25: 161-5
- 32 Valentini V, Cassoni A, Marianetti TM, Terenzi V, Fadda MT, Iannetti G. Craniomaxillofacial fibrous dysplasia: Conservative treatment or radical surgery? A retrospective study on 68 patients. Plast Reconstr Surg 2009; 123: 653-60
- 33 Chen YR, Noordhoff MS. Treatment of crani-omaxillofacial fibrous dysplasia: How early and how extensive?. Plast Reconstr Surg 1990; 86: 835-44
- 34 Amit M, Collins MT, FitzGibbon EJ, Butman JA, Fliss DM, Gil Z. Surgery versus watchful waiting in patients with craniofacial fibrous dysplasia - A meta-analysis. PLoS One 2011; 6: e25179
- 35 Béquignon E, Cardinne C, Lachiver X, Wagner I, Chabolle F, Baujat B. Craniofacial fibrous dysplasia surgery: A functional approach. Eur Ann Otorhinolaryngol Head Neck Dis 2013; 130: 215-20
- 36 Menon S, Venkatswamy S, Ramu V, Banu K, Ehtaih S, Kashyap VM. Craniofacial fibrous dysplasia: Surgery and literature review. Ann Maxillofac Surg 2013; 3: 66-71
- 37 Zeng HF, Lu JJ, Teng L, Jin XL, Xu JJ, Zhang C. et al Surgical treatment of craniomaxillofacial fibrous dysplasia: Functionally or aesthetically?. J Craniofac Surg 2013; 24: 758-62
- 38 Gui H, Zhang S, Shen SG, Wang X, Bautista JS, Voss PJ. Real-time image-guided recontouring in the management of craniofacial fibrous dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol 2013; 116: 680-5
- 39 Yabut Jr SM, Kenan S, Sissons HA, Lewis MM. Malignant transformation of fibrous dysplasia. A case report and review of the literature. Clin Orthop Relat Res 1988; 228: 281-9
- 40 Sadeghi SM, Hosseini SN. Spontaneous conversion of fibrous dysplasia into osteosarcoma. J Craniofac Surg 2011; 22: 959-61
- 41 Park BY, Cheon YW, Kim YO, Pae NS, Lee WJ. Prognosis for craniofacial fibrous dysplasia after incomplete resection: Age and serum alkaline phosphatase. Int J Oral Maxillofac Surg 2010; 39: 221-6
- 42 Harris WH, Robert Dudley Jr H, Barry RJ. The natural history of fibrous dysplasia. J Bone Joint Surg Am 1962; 44: 207-33
- 43 Bhattacharyya N, Wiench M, Dumitrescu C, Connolly BM, Bugge TH, Patel HV. et al Mechanism of FGF23 processing in fibrous dysplasia. J Bone Miner Res 2012; 27: 1132-41
- 44 Robey PG, Kuznetsov S, Riminucci M, Bianco P. The role of stem cells in fibrous dysplasia of bone and the Mccune-Albright syndrome. Pediatr Endocrinol Rev 2007; 4 Suppl (Suppl. 04) 386-94
- 45 Choremis K, Papadatos C, Caterellos C. Familial multilocular cystic disease of the jaws. Helv Paediatr Acta 1959; 14: 396-9
- 46 Jones WA, Gerrie J, Pritchard J. Cherubism - familial fibrous dysplasia of the jaws. J Bone Joint Surg Br 1950; 32-B: 334-47
- 47 Irfan S, Cassels-Brown A, Hayward J, Corrigan A. Orbital Cherubism. Orbit 1997; 16: 109-12
- 48 Emoto Y, Emoto H, Fujle W, Wakakura M. Uncorrectable Oblique Astigmatism and Impaired Binocular Vision in Case of Orbital Cherubism. Neuro-ophthalmology 2007; 31: 191-5
- 49 Lenouvel D, Chapireau D, Bentley R. Late reactivation of cherubism in a patient with new-onset polycystic ovary syndrome. J Oral Maxillofac Surg 2015; 73: 1957-61
- 50 Li CY, Yu SF. A novel mutation in the SH3BP2 gene causes cherubism: Case report. BMC Med Genet 2006; 7: 84
- 51 Tiziani V, Reichenberger E, Buzzo CL, Niazi S, Fukai N, Stiller M. et al The gene for cherubism maps to chromosome 4p16. Am J Hum Genet 1999; 65: 158-66
- 52 van Capelle CI, Hogeman PH, van der Sijs-Bos CJ, Heggelman BG, Idowu B, Slootweg PJ. et al Neurofibromatosis presenting with a cherubism phenotype. Eur J Pediatr 2007; 166: 905-9
- 53 Carroll AL, Sullivan TJ. Orbital involvement in cherubism. Clin Experiment Ophthalmol 2001; 29: 38-40
- 54 Hero M, Suomalainen A, Hagström J, Stoor P, Kontio R, Alapulli H. et al Anti-tumor necrosis factor treatment in cherubism - clinical, radiological and histological findings in two children. Bone 2013; 52: 347-53
- 55 Yoshitaka T, Ishida S, Mukai T, Kittaka M, Reichenberger EJ, Ueki Y. Etanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss. J Bone Miner Res 2014; 29: 1170-82
- 56 Fernandes Gomes M, Ferraz de Brito Penna Forte L, Hiraoka CM, Augusto Claro F, Costa Armond M. Clinical and surgical management of an aggressive cherubism treated with autogenous bone graft and calcitonin. ISRN Dent 2011; 2011: 340960
- 57 Etoz OA, Dolanmaz D, Gunhan O. Treatment of cherubism with salmon calcitonin: A case report. Eur J Dent 2011; 5: 486-91